Overview: Upper Respiratory Antigen Panel TestIntroduction: The Upper Respiratory Antigen Panel Test screens respiratory antigens to diagnose infections, causing cough or fever. Aligned with 2023 IDSA guidelines, it uses rapid antigen testing for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in clinical diagnostics for patients with suspected respiratory infections. Note: Test Parameters, Sample Stability, and Methodology are not specified in input data; typically involves antigen detection via immunoassay.
Other Names: Respiratory Antigen Panel, Upper Respiratory Infection Screen.
FDA Status: Laboratory-developed test (LDT), meeting clinical diagnostic standards for accuracy.
Historical Milestone: Respiratory antigen testing began in the 1980s with viral diagnostic research. Rapid antigen methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Screens respiratory antigens to diagnose infections, guides treatment, and evaluates patients with cough or fever.
Test Parameters: Not specified in input data; typically includes antigens for influenza, RSV, or other respiratory pathogens.
Pretest Condition: No fasting required. Collect nasopharyngeal or throat swab. Report history of cough, fever, or respiratory symptoms.
Specimen: Nasopharyngeal Swab (sterile swab/transport medium, 1-2 swabs), Throat Swab (sterile swab/transport medium, 1-2 swabs). Transport in a biohazard container.
Sample Stability at Room Temperature: Not specified in input data; typically 2 hours for swabs.
Sample Stability at Refrigeration: Not specified in input data; typically 24 hours for swabs.
Sample Stability at Frozen: Not specified in input data; typically not frozen for swabs.
Medical History: Document cough, fever, or history of respiratory infections. Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, respiratory infection implications, and risks of sample collection.
Procedural Considerations: Uses rapid antigen testing or immunofluorescence to detect respiratory pathogen antigens. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for respiratory infection diagnosis.
Factors Affecting Result Accuracy: Improper swab collection or contamination can affect results. Low antigen load may reduce sensitivity.
Clinical Significance: Positive antigens confirm respiratory infection, guiding antiviral or supportive therapy. Negative results may require PCR or culture.
Specialist Consultation: Consult an infectious disease specialist or pulmonologist for result interpretation and treatment planning.
Additional Supporting Tests: Respiratory PCR, viral culture, or chest imaging to confirm respiratory infection diagnosis.
Test Limitations: Limited to detectable antigens; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Respiratory Infection Guidelines, 2023; Clinical Infectious Diseases, Uyeki TM, 2022.
